ALBUQUERQUE, N.M.--(BUSINESS WIRE)--SolaranRx, Inc. has been chosen by Informa and Kantar Health as one of the 2014 Top 10 Most Interesting Oncology Projects to Watch for its lead compound, SRX-1177, to treat metastatic melanoma.
SolaranRX CEO Les Stewart will present at Informa’s Therapeutic Area Partnerships meeting at the Hyatt Regency in Boston on Thursday, November 20 within Track 3 (Oncology). He will discuss SRX-1177, a novel peptide linked to a radioisotope that preferentially attaches to melanocortin-1 (MC1) receptors, which are over-expressed in about 80 percent of melanoma cells. SRX-1177 can be used to identify melanoma patients with MC1 receptors. Those patients can then be injected with therapeutic doses of SRX-1177 to deliver targeted radiation, while minimizing the impact on healthy cells. This merger of therapy and diagnostics creates a unique theranostic product for metastatic melanoma.
Help employers find you! Check out all the jobs and post your resume.
SolaranRX CEO Les Stewart will present at Informa’s Therapeutic Area Partnerships meeting at the Hyatt Regency in Boston on Thursday, November 20 within Track 3 (Oncology). He will discuss SRX-1177, a novel peptide linked to a radioisotope that preferentially attaches to melanocortin-1 (MC1) receptors, which are over-expressed in about 80 percent of melanoma cells. SRX-1177 can be used to identify melanoma patients with MC1 receptors. Those patients can then be injected with therapeutic doses of SRX-1177 to deliver targeted radiation, while minimizing the impact on healthy cells. This merger of therapy and diagnostics creates a unique theranostic product for metastatic melanoma.
Help employers find you! Check out all the jobs and post your resume.
